Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastrointestinal adenocarcinoma; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, and BioInvent. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Metrics to compare | TRNG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTRNGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.0x | −2.8x | −0.6x | |
PEG Ratio | 0.28 | 0.03 | 0.00 | |
Price/Book | −71.7x | 1.4x | 2.6x | |
Price / LTM Sales | 34.1x | 7.9x | 3.3x | |
Upside (Analyst Target) | 96.0% | 184.5% | 40.0% | |
Fair Value Upside | Unlock | 10.3% | 3.2% | Unlock |